Close Menu

NEW YORK – Guardant Health reported after the close of the market on Thursday that its second quarter 2020 revenues were up 23 percent year over year.

The liquid biopsy and cancer early detection firm reported total revenues of $66.3 million for the quarter ended June 30 compared to $54.0 million in the same period of 2019, beating the $59.2 million that Wall Street had predicted on average.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.